Compare Cipla with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PANACEA BIOTECH - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PANACEA BIOTECH CIPLA/
PANACEA BIOTECH
 
P/E (TTM) x 23.1 10.5 220.1% View Chart
P/BV x 2.5 2.2 114.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 CIPLA   PANACEA BIOTECH
EQUITY SHARE DATA
    CIPLA
Mar-19
PANACEA BIOTECH
Mar-19
CIPLA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs678354 191.7%   
Low Rs484138 350.1%   
Sales per share (Unadj.) Rs198.274.6 265.8%  
Earnings per share (Unadj.) Rs18.56.7 277.3%  
Cash flow per share (Unadj.) Rs35.015.5 225.8%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs186.357.2 325.7%  
Shares outstanding (eoy) m805.7061.25 1,315.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.93.3 88.9%   
Avg P/E ratio x31.436.8 85.2%  
P/CF ratio (eoy) x16.615.9 104.6%  
Price / Book Value ratio x3.14.3 72.5%  
Dividend payout %16.20-   
Avg Mkt Cap Rs m468,03115,061 3,107.5%   
No. of employees `00022.62.3 978.6%   
Total wages/salary Rs m28,5651,471 1,942.2%   
Avg. sales/employee Rs Th7,053.11,973.6 357.4%   
Avg. wages/employee Rs Th1,261.5635.6 198.5%   
Avg. net profit/employee Rs Th659.1176.8 372.8%   
INCOME DATA
Net Sales Rs m159,7104,567 3,497.0%  
Other income Rs m4,76645 10,637.7%   
Total revenues Rs m164,4754,612 3,566.4%   
Gross profit Rs m30,9732,030 1,526.0%  
Depreciation Rs m13,263540 2,456.1%   
Interest Rs m1,6841,048 160.7%   
Profit before tax Rs m20,791486 4,276.3%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,69577 7,386.9%   
Profit after tax Rs m14,924409 3,648.1%  
Gross profit margin %19.444.4 43.6%  
Effective tax rate %27.415.9 172.7%   
Net profit margin %9.39.0 104.3%  
BALANCE SHEET DATA
Current assets Rs m124,2662,415 5,146.7%   
Current liabilities Rs m37,7159,077 415.5%   
Net working cap to sales %54.2-145.9 -37.1%  
Current ratio x3.30.3 1,238.7%  
Inventory Days Days9165 139.2%  
Debtors Days Days9571 133.8%  
Net fixed assets Rs m105,1908,333 1,262.3%   
Share capital Rs m1,61161 2,628.7%   
"Free" reserves Rs m148,5113,443 4,313.8%   
Net worth Rs m150,1233,504 4,284.3%   
Long term debt Rs m38,301461 8,304.6%   
Total assets Rs m239,63313,755 1,742.1%  
Interest coverage x13.31.5 911.6%   
Debt to equity ratio x0.30.1 193.8%  
Sales to assets ratio x0.70.3 200.7%   
Return on assets %6.910.6 65.4%  
Return on equity %9.911.7 85.2%  
Return on capital %11.838.7 30.6%  
Exports to sales %34.720.9 166.1%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs m55,419954 5,809.7%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m57,4101,203 4,772.1%   
Fx outflow Rs m19,041467 4,080.3%   
Net fx Rs m38,368736 5,210.5%   
CASH FLOW
From Operations Rs m16,9111,049 1,612.5%  
From Investments Rs m-16,687-54 31,190.3%  
From Financial Activity Rs m-3,487-1,011 344.8%  
Net Cashflow Rs m-3,451-20 17,518.3%  

Share Holding

Indian Promoters % 16.0 74.5 21.5%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 0.6 2,033.3%  
FIIs % 23.7 1.3 1,823.1%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 23.6 111.0%  
Shareholders   161,166 10,259 1,571.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  GSK PHARMA  DR. DATSONS LABS  DR. REDDYS LAB  ABBOTT INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 19, 2019 03:31 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS